Stem Cells International / 2016 / Article / Tab 1

Research Article

Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation

Table 1

Clinical characteristics of study patients ().

Patient characteristics%

Gender
 Female16844.6
 Male20955.4
Age at HSCT
3513936.9
3523863.1
EBMT risk score
215541.1
222258.9
Indication for HSCT
 AML/MDS15741.7
 MPD195.0
 ALL7419.6
 Lymphoma6316.7
 MM184.8
 SAA4511.9
 Others10.3
Donor relation
 Matched sibling18148.0
 Nonmatched sibling19652.0
Conditioning regimen
 TBI-12 Gy based12533.2
 Fludarabine based7419.6
 Myeloablative24865.8
Type 2 DM history154.0
Smoking history246.4
Posttransplant CMV reactivation
 Within 1 year18849.9
 Within 2 years19050.4
PTLD after HSCT
 Within 1 year143.7
 Within 2 years154.0

HSCT: hematopoietic stem cell transplantation; MDS: myelodysplastic syndromes; EBMT: European Group for Blood and Marrow Transplantation; AML: acute myeloid leukemia; MPD: myeloproliferative disorder; ALL: acute lymphoblastic leukemia; MM: multiple myeloma; SAA: severe aplastic anemia; TBI: total body irradiation; CMV: cytomegalovirus; DM: diabetes mellitus; PTLD: posttransplant lymphoproliferative disorder.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.